Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Gossamer Bio, Inc.
Gossamer Bio, Inc. News
Gossamer Bio, Inc. Quantitative Score
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Gossamer Bio, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Gossamer Bio, Inc. Financials
Table Compare
Compare GOSS metrics with: | |||
|---|---|---|---|
Earnings & Growth | GOSS | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | GOSS | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | GOSS | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | GOSS | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Gossamer Bio, Inc. Income
Gossamer Bio, Inc. Balance Sheet
Gossamer Bio, Inc. Cash Flow
Gossamer Bio, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Gossamer Bio, Inc. Executives
| Name | Role |
|---|---|
| Mr. Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman |
| Mr. Bryan Giraudo | Chief Operating Officer & Chief Financial Officer |
| Dr. Richard Aranda M.D. | Chief Medical Officer |
| Mr. Christian Waage J.D. | Executive Vice President of Technical Operations & Administration |
| Mr. Jeff Boerneke | General Counsel & Secretary |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman | Male | 1958 | 962K |
| Mr. Bryan Giraudo | Chief Operating Officer & Chief Financial Officer | Male | 1975 | 739.62K |
| Dr. Richard Aranda M.D. | Chief Medical Officer | 1960 | 677.49K | |
| Mr. Christian Waage J.D. | Executive Vice President of Technical Operations & Administration | Male | 1967 | 583.16K |
| Mr. Jeff Boerneke | General Counsel & Secretary | Male | -- |
Gossamer Bio, Inc. Insider Trades
| Date | 25 Jun |
| Name | Daniel Thomas O |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 115000 |
| Date | 25 Jun |
| Name | Nathan Steven D |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 115000 |
| Date | 25 Jun |
| Name | Cox Russell J. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 115000 |
| Date | 25 Jun |
| Name | Quisel John D |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 115000 |
| Date | 25 Jun |
| Name | Milligan Sandra |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 115000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 25 Jun | Daniel Thomas O | Director | Acquired | A-Award | 115000 |
| 25 Jun | Nathan Steven D | Director | Acquired | A-Award | 115000 |
| 25 Jun | Cox Russell J. | Director | Acquired | A-Award | 115000 |
| 25 Jun | Quisel John D | Director | Acquired | A-Award | 115000 |
| 25 Jun | Milligan Sandra | Director | Acquired | A-Award | 115000 |